New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
15th May 2023
28th April 2023
4th April 2023
France: The National Drug Safety Agency (ANSM) is warning of a possible shortage of CBD-only medicines in its medical cannabis pilot programme and suggests alternatives, such as Epidyolex and preparations that contain THC, for patients already in the programme. The anticipated shortage follows the withdrawal from the programme of Little Green Pharma, which provides approximately 60% of the products prescribed, press reports.
3rd February 2023
25th January 2023
9th January 2023
16th December 2022
14th December 2022
France: The highest administrative court in France, the Council of State, was due to rule today on the legitimacy of the Decree of 30th December 2021 banning the sale, possession and consumption of hemp flowers, media reports. The ban was temporarily suspended by the Council of State in January 2022 following an appeal by several industry members.
22nd November 2022
French Polynesia: With 33 votes and 20 abstentions, the Assembly has approved a law legalising the medical and industrial use of cannabis. Cultivation of hemp with up to 0.3% THC will be allowed for the production of non-ingestible products, and cultivation with higher amounts of THC will be allowed for the manufacture of medicines.
21st November 2022
25th October 2022
France: Different political parties have put forward various amendments (181, 755, 1046, 2866, 2879 and 2893) to the 2023 Social Security Financing Bill that would require the government to produce a report analysing the impact of the medical cannabis experiment. Two other amendments (AS688, AS1650), both with the aim of extending the experiment, were adopted last week.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.